The partners are pushing to expand Enhertu’s list of indications beyond its standing uses in breast, lung and gastric cancers ...

The breast cancer market has experienced robust growth, fueled by increased awareness and early detection efforts. Advances in diagnostic and treatme ...

Datroway demonstrated durable antitumor activity and an acceptable safety profile in advanced NSCLC with actionable genomic ...

The pharmaceutical industry is evolving continuously with the advancements in drug discovery with Artificial Intelligence (AI ...

In the Phase III SERENA-6 trial, camizestrant—in combination with CDK-inhibitors—beat out current standard-of-care treatments in terms of progression-free survival, according to AstraZeneca.

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET. 0804 GMT – The results of AstraZeneca’s upcoming cancer drug ...

The latest news for pharma industry insiders.

Sifting through countless of stocks in the Pharmaceuticals industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about ...

The first patient, who had xerostomia linked with Sjögren's disease, received the autologous cell therapy as part of a Phase 0 trial. The trial will test four dose levels and include up to 18 patients ...

This therapy consists of a monoclonal antibody attached to a chemotherapy drug. Datopotamab deruxtecan (Datroway) and sacituzumab govitecan (Trodelvy) are used to treat certain types of advanced ...

Therapies approved in January included: Datroway (datopotamab deruxtecan) for unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer from Astrazeneca plc and Daiichi ...